Symbol="RARE"
AssetType="Common Stock"
Name="Ultragenyx"
Description="Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California."
CIK="1515673"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="60 LEVERONI COURT, NOVATO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="3053521000"
EBITDA="-647024000"
PERatio="None"
PEGRatio="-0.24"
BookValue="3.121"
DividendPerShare="0"
DividendYield="0"
EPS="-9.87"
RevenuePerShareTTM="5.47"
ProfitMargin="-1.873"
OperatingMarginTTM="-1.736"
ReturnOnAssetsTTM="-0.301"
ReturnOnEquityTTM="-1.414"
RevenueTTM="383890000"
GrossProfitTTM="-370780000"
DilutedEPSTTM="-9.87"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.257"
AnalystTargetPrice="91.32"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="9.3"
PriceToBookRatio="6.8"
EVToRevenue="6.79"
EVToEBITDA="-3.744"
Beta="0.865"
num_52WeekHigh="56.42"
num_52WeekLow="33.36"
num_50DayMovingAverage="47.53"
num_200DayMovingAverage="43.06"
SharesOutstanding="70814000"
DividendDate="None"
ExDividendDate="None"
symbol="RARE"
open="43.46"
high="44.30"
low="42.92"
price="43.12"
volume="373278.00"
latest_trading_day="2023-07-31"
previous_close="43.11"
change="0.01"
change_percent="0.0232%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="48"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="52"
Volume_recent_avg="609594"
Change_recent_avg="-0.07"
Delta_recent_avg="1.76"
Variance_recent_avg="0.88"
Change_ratio_recent_avg="-0.19"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="52"
Aroon_momentum_negative="48"
image_negative_thumbnail_id_1="1132"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0165.jpeg"
image_negative_thumbnail_id_2="520"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0085.jpeg"
image_neutral_thumbnail_id_1="521"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_neutral_thumbnail_id_2="583"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_positive_thumbnail_id_1="1011"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0173.jpeg"
image_positive_thumbnail_id_2="610"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0098.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1181"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
